***Background.*** Varicella is a worldwide endemic infection self-limited in the vast majority of cases. However, serious complications are described in otherwise healthy people that add to a significant societal burden of disease. In many countries, varicella universal mass vaccination (vUMV) has now been implemented for years. Nevertheless, vUMV remains debated in Europe and few data are available on the real burden of the infection and the potential benefits achievable by national vaccination campaigns. We propose here to assess the burden of varicella over the whole Belgian area through analysis of due hospitalized cases during a one-year period.

***Methods.*** Pediatric varicella-related hospitalized cases were actively collected (prospectively then retrospectively) through a national network from November 2011 to October 2012. Inclusion criteria were either acute varicella episode or related complications up to 3weeks after the rash.

***Results.*** 101 hospitals participated, covering 97.7% of the total pediatric beds available in Belgium. 553 children were recorded with a median age of 2.1 years. Incidence of pediatric varicella-due hospitalizations reached 29.5/ 10^5^ people-year with the highest impact among the 0-4y old (global incidence and odds of hospitalization: 79/ 10^5^ people-year and 1.56/100 varicella-cases; respectively). Only 16% of the cohort had underlying chronic condition. 65% of children had ≥1 complication justifying their admission, 49% were bacterial super-infections and 10% neurological disorders. Many children were also hospitalized for anorexia and dehydration. Incidence of complicated hospitalized cases was 19/ 10^5^ people-year. Only one fourth of children received acyclovir but 58% were under antibiotics. ICU admission and surgery were required in 4% and 3%, respectively. One child died from severe bacterial sepsis (mortality and fatality rates: 0.5/10^6^ and 0.2%; respectively) and 1% had sequelae at discharge.

***Conclusion.*** Varicella demonstrated a substantial burden of disease in Belgian children, especially among the youngest. Our thorough nation-wide study, run in a country without vUMV policy, offers recent data to fuel the debate over vUMV in Europe.
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